OncoTRACE is a non-invasive liquid biopsy-based test that allows a personalized and sensitive monitoring of the patient’s response to the treatment from circulating tumor free DNA. Thanks to OncoTRACE, you can identify:

- Tumor’s recurrence
- Potential mechanisms of resistance
- New possibilities of treatment

**WHY TO MAKE A PERSONALIZED ONCOTRACE?**

During the evolution of the disease, each metastatic clone evolves and alters its molecular genotype, making clinical decisions challenging. To fully enable precision medicine, it is desirable to have an easily accessible and minimally invasive way to determine and follow the molecular makeup of a patient’s tumor longitudinally. Thanks to personalized OncoTRACE it is possible to follow the whole burden of the disease by a simple blood testing and to find solutions for further treatments.

**WHEN TO PERFORM ONCOTRACE?**

Although there are no fixed guidelines, based on our internal studies, OncoTRACE should ideally be performed in the middle of the treatment and about two weeks after the last taking. Subsequently, it will depend on the treatment, the cancer type and the anamnesis of the patient. For the moment we propose an average periodicity of three months, but this can be discussed with the oncologist case by case.

**MATERIAL**

2 blood samples (2 Streck tubes of 10 ml each)

**PERSONALIZED LIQUID BIOPSY**

- Next-generation sequencing
- Each test is designed on the unique molecular signature of your tumor, coming from a previous genomic sequencing done through a solid or liquid biopsy analysis
- Targets more individual-specific mutations (12) leading to a higher probability of ctDNA detection to monitor recurrence
- In addition 40 genes associated with mutations (SNV, Indel and CNV) of resistance and sensitivity to targeted therapies

**INTEGRATED THERANOSTIC REPORT**

- Liquid biopsy view
- Dynamic evolution of the personalized variants
- Reporting of new variant(s) associated with resistance and/or new treatment options
- Treatment options for targeted therapies
- Clinical trials availability

OncoTRACE is IVD CE-marked and processed in an ISO 15189 accredited laboratory.
WHY IS ONCOTRACE UNIQUE?

OncoDNA is offering the first personalized analysis of the liquid biopsy based on the sequencing of the solid tumor. In addition to the core panel, 12 to 15 variants previously identified from the tumor are used to monitor the evolution of the disease.

HOW LONG DOES IT TAKE TO GET THE RESULTS?

Starting from our OncoSTRAT&GO results as well as any other sequencing dataset generated by other sequencing services, we are committed to sending the report within 7 working days once OncoDNA has received and QC checked the liquid biopsy sample and all the required clinical information.

Starting from sequencing data provided by another platform please count 3 additional weeks for primers design and synthesis.

WHO IS THIS TEST FOR?

For every metastatic solid tumor in adults that has previously been sequenced (from OncoSTRAT&GO sequencing, as well as any other sequencing dataset generated by other sequencing services).